Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. / Laakso, M; Zilinskaite, J; Hansen, T; Boesgaard, T Welløv; Vänttinen, M; Stancáková, A; Jansson, P-A; Pellmé, F; Kuulasmaa, T; Hribal, M L; Sesti, G; Stefan, N; Fritsche, A; Häring, H; Pedersen, Oluf; Smith, U; EUGENE2 Consortium ; Holst, Jens Juul.

In: Diabetologia, Vol. 51, No. 3, 2008, p. 502-11.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Laakso, M, Zilinskaite, J, Hansen, T, Boesgaard, TW, Vänttinen, M, Stancáková, A, Jansson, P-A, Pellmé, F, Kuulasmaa, T, Hribal, ML, Sesti, G, Stefan, N, Fritsche, A, Häring, H, Pedersen, O, Smith, U, EUGENE2 Consortium & Holst, JJ 2008, 'Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study', Diabetologia, vol. 51, no. 3, pp. 502-11. https://doi.org/10.1007/s00125-007-0899-2

APA

Laakso, M., Zilinskaite, J., Hansen, T., Boesgaard, T. W., Vänttinen, M., Stancáková, A., Jansson, P-A., Pellmé, F., Kuulasmaa, T., Hribal, M. L., Sesti, G., Stefan, N., Fritsche, A., Häring, H., Pedersen, O., Smith, U., EUGENE2 Consortium, & Holst, J. J. (2008). Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia, 51(3), 502-11. https://doi.org/10.1007/s00125-007-0899-2

Vancouver

Laakso M, Zilinskaite J, Hansen T, Boesgaard TW, Vänttinen M, Stancáková A et al. Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia. 2008;51(3):502-11. https://doi.org/10.1007/s00125-007-0899-2

Author

Laakso, M ; Zilinskaite, J ; Hansen, T ; Boesgaard, T Welløv ; Vänttinen, M ; Stancáková, A ; Jansson, P-A ; Pellmé, F ; Kuulasmaa, T ; Hribal, M L ; Sesti, G ; Stefan, N ; Fritsche, A ; Häring, H ; Pedersen, Oluf ; Smith, U ; EUGENE2 Consortium ; Holst, Jens Juul. / Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. In: Diabetologia. 2008 ; Vol. 51, No. 3. pp. 502-11.

Bibtex

@article{8832da00eedd11ddbf70000ea68e967b,
title = "Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study",
abstract = "AIMS/HYPOTHESIS: We examined the phenotype of individuals with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) with regard to insulin release and insulin resistance. METHODS: Non-diabetic offspring (n=874; mean age 40+/-10.4 years; BMI 26.6+/-4.9 kg/m(2)) of type 2 diabetic patients from five different European Centres (Denmark, Finland, Germany, Italy and Sweden) were examined with regard to insulin sensitivity (euglycaemic clamps), insulin release (IVGTT) and glucose tolerance (OGTT). The levels of glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) were measured during the OGTT in 278 individuals. RESULTS: Normal glucose tolerance was found in 634 participants, while 110 had isolated IFG, 86 had isolated IGT and 44 had both IFG and IGT, i.e. about 28% had a form of reduced glucose tolerance. Participants with isolated IFG had lower glucose-corrected first-phase (0-10 min) and higher second-phase insulin release (10-60 min) during the IVGTT, while insulin sensitivity was reduced in all groups with abnormal glucose tolerance. Similarly, GLP-1 but not GIP levels were reduced in individuals with abnormal glucose tolerance. CONCLUSIONS/INTERPRETATION: The primary mechanism leading to hyperglycaemia in participants with isolated IFG is likely to be impaired basal and first-phase insulin secretion, whereas in isolated IGT the primary mechanism leading to postglucose load hyperglycaemia is insulin resistance. Reduced GLP-1 levels were seen in all groups with abnormal glucose tolerance and were unrelated to the insulin release pattern during an IVGTT.",
author = "M Laakso and J Zilinskaite and T Hansen and Boesgaard, {T Well{\o}v} and M V{\"a}nttinen and A Stanc{\'a}kov{\'a} and P-A Jansson and F Pellm{\'e} and T Kuulasmaa and Hribal, {M L} and G Sesti and N Stefan and A Fritsche and H H{\"a}ring and Oluf Pedersen and U Smith and {EUGENE2 Consortium} and Holst, {Jens Juul}",
note = "Keywords: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Family; Fasting; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose Intolerance; Glucose Tolerance Test; Humans; Insulin; Male; Middle Aged; Reference Values",
year = "2008",
doi = "10.1007/s00125-007-0899-2",
language = "English",
volume = "51",
pages = "502--11",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study

AU - Laakso, M

AU - Zilinskaite, J

AU - Hansen, T

AU - Boesgaard, T Welløv

AU - Vänttinen, M

AU - Stancáková, A

AU - Jansson, P-A

AU - Pellmé, F

AU - Kuulasmaa, T

AU - Hribal, M L

AU - Sesti, G

AU - Stefan, N

AU - Fritsche, A

AU - Häring, H

AU - Pedersen, Oluf

AU - Smith, U

AU - EUGENE2 Consortium

AU - Holst, Jens Juul

N1 - Keywords: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Family; Fasting; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose Intolerance; Glucose Tolerance Test; Humans; Insulin; Male; Middle Aged; Reference Values

PY - 2008

Y1 - 2008

N2 - AIMS/HYPOTHESIS: We examined the phenotype of individuals with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) with regard to insulin release and insulin resistance. METHODS: Non-diabetic offspring (n=874; mean age 40+/-10.4 years; BMI 26.6+/-4.9 kg/m(2)) of type 2 diabetic patients from five different European Centres (Denmark, Finland, Germany, Italy and Sweden) were examined with regard to insulin sensitivity (euglycaemic clamps), insulin release (IVGTT) and glucose tolerance (OGTT). The levels of glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) were measured during the OGTT in 278 individuals. RESULTS: Normal glucose tolerance was found in 634 participants, while 110 had isolated IFG, 86 had isolated IGT and 44 had both IFG and IGT, i.e. about 28% had a form of reduced glucose tolerance. Participants with isolated IFG had lower glucose-corrected first-phase (0-10 min) and higher second-phase insulin release (10-60 min) during the IVGTT, while insulin sensitivity was reduced in all groups with abnormal glucose tolerance. Similarly, GLP-1 but not GIP levels were reduced in individuals with abnormal glucose tolerance. CONCLUSIONS/INTERPRETATION: The primary mechanism leading to hyperglycaemia in participants with isolated IFG is likely to be impaired basal and first-phase insulin secretion, whereas in isolated IGT the primary mechanism leading to postglucose load hyperglycaemia is insulin resistance. Reduced GLP-1 levels were seen in all groups with abnormal glucose tolerance and were unrelated to the insulin release pattern during an IVGTT.

AB - AIMS/HYPOTHESIS: We examined the phenotype of individuals with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) with regard to insulin release and insulin resistance. METHODS: Non-diabetic offspring (n=874; mean age 40+/-10.4 years; BMI 26.6+/-4.9 kg/m(2)) of type 2 diabetic patients from five different European Centres (Denmark, Finland, Germany, Italy and Sweden) were examined with regard to insulin sensitivity (euglycaemic clamps), insulin release (IVGTT) and glucose tolerance (OGTT). The levels of glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) were measured during the OGTT in 278 individuals. RESULTS: Normal glucose tolerance was found in 634 participants, while 110 had isolated IFG, 86 had isolated IGT and 44 had both IFG and IGT, i.e. about 28% had a form of reduced glucose tolerance. Participants with isolated IFG had lower glucose-corrected first-phase (0-10 min) and higher second-phase insulin release (10-60 min) during the IVGTT, while insulin sensitivity was reduced in all groups with abnormal glucose tolerance. Similarly, GLP-1 but not GIP levels were reduced in individuals with abnormal glucose tolerance. CONCLUSIONS/INTERPRETATION: The primary mechanism leading to hyperglycaemia in participants with isolated IFG is likely to be impaired basal and first-phase insulin secretion, whereas in isolated IGT the primary mechanism leading to postglucose load hyperglycaemia is insulin resistance. Reduced GLP-1 levels were seen in all groups with abnormal glucose tolerance and were unrelated to the insulin release pattern during an IVGTT.

U2 - 10.1007/s00125-007-0899-2

DO - 10.1007/s00125-007-0899-2

M3 - Journal article

C2 - 18080106

VL - 51

SP - 502

EP - 511

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 3

ER -

ID: 10027003